The U.S. Food and Drug Administration (USFDA) recently approved the first injectable formulation of cabotegravir and rilpivirine for the management of human immunodeficiency virus type 1 (HIV-1) infection in adults. This injectable regimen can replace the current antiretroviral regimen in virologically suppressed (HIV-1 RNA < 50 copies/mL) patients with no history of treatment failure or no known or suspected resistance to cabotegravir and rilpivirine.
The USFDA also approved a tablet formulation of cabotegravir, which should be taken in combination with oral rilpivirine one month prior , to ensure that the medications are well-tolerated before switching to extended-release injectable cabotegravir and rilpivirine combination. The injectable regimen was administered to a total of 1,182 virologically suppressed HIV-infected adults across two randomized, open-label, controlled clinical…
